What is HC Wainwright’s Forecast for UTHR Q1 Earnings?

United Therapeutics Co. (NASDAQ:UTHR) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for United Therapeutics in a research note issued on Thursday, February 27th. HC Wainwright analyst A. Fein forecasts that the biotechnology company will post earnings of $7.07 per share for the quarter. HC Wainwright has a “Buy” rating and a $425.00 price objective on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. HC Wainwright also issued estimates for United Therapeutics’ Q2 2025 earnings at $7.39 EPS, Q3 2025 earnings at $7.33 EPS, Q4 2025 earnings at $6.89 EPS and FY2028 earnings at $37.60 EPS.

A number of other brokerages have also commented on UTHR. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. UBS Group lifted their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Stock Performance

Shares of UTHR opened at $310.03 on Monday. The firm has a market cap of $13.92 billion, a P/E ratio of 13.62, a PEG ratio of 0.97 and a beta of 0.57. United Therapeutics has a twelve month low of $221.53 and a twelve month high of $417.82. The firm’s 50 day moving average price is $358.58 and its two-hundred day moving average price is $360.88.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. During the same quarter in the previous year, the business posted $4.36 EPS.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Wealthfront Advisers LLC boosted its position in United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares during the period. Norges Bank acquired a new stake in shares of United Therapeutics during the 4th quarter worth about $151,764,000. FMR LLC lifted its stake in shares of United Therapeutics by 36.5% during the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock worth $519,170,000 after buying an additional 393,777 shares during the last quarter. World Investment Advisors LLC bought a new stake in shares of United Therapeutics during the 3rd quarter worth about $139,206,000. Finally, Thrivent Financial for Lutherans grew its stake in United Therapeutics by 1,325.5% in the 4th quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock valued at $72,085,000 after buying an additional 189,967 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the transaction, the executive vice president now owns 36,710 shares of the company’s stock, valued at $13,743,122.70. The trade was a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 124,164 shares of company stock worth $45,278,893 over the last quarter. 11.90% of the stock is currently owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.